Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Femasys Inc. (NASDAQ: FEMY) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As an emerging growth company and smaller reporting company, Femasys files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events affecting its business, capital structure and listing status.
Through these filings, investors can review detailed information about Femasys’ women’s health portfolio, including fertility products such as FemaSeed Intratubal Insemination and FemVue, and the FemBloc permanent birth control system. Current reports on Form 8-K have described milestones like FDA 510(k) clearance for the FemVue Controlled diagnostic device, IDE approval to advance the final phase of the FINALE pivotal trial for FemBloc, and international regulatory approvals for FemBloc in Europe and the UK. Other 8-K filings outline financing transactions, including senior secured convertible notes and associated warrants, as well as underwritten equity offerings.
Femasys’ filings also disclose its Nasdaq Capital Market listing under the symbol FEMY, notices related to continued listing requirements, and responses such as capital raises or bid-price compliance plans. Registration statements on Form S-1 and S-1/A provide further detail on offered securities, use of proceeds, risk factors and forward-looking statements related to the company’s fertility and permanent birth control strategy.
On Stock Titan, these FEMY filings are updated in real time from EDGAR and paired with AI-powered summaries that highlight key points in lengthy documents. Users can quickly locate 10-K and 10-Q reports, 8-K event disclosures, registration statements and other filings, and use AI-generated explanations to understand complex sections on clinical development, regulatory pathways, financing terms and Nasdaq compliance without reading every page.
Femasys Inc. reported results for the quarter ended June 30, 2025. Quarterly sales rose to $409,268 (six months $750,532), driven by increased FemaSeed and FemVue sales. The company recorded a net loss of $(4,585,922) for the quarter and $(10,482,761) for the six months, with six-month net loss per share of $(0.39). Cash and cash equivalents were $3,218,067, total assets $13,780,409, total liabilities $12,272,974, and an accumulated deficit of $137,681,018. Inventory increased to $5,232,738.
The filing highlights regulatory and commercial milestones: CE mark certification under EU MDR for the FemBloc delivery system (March 2025) and for the class III blended polymer component (June 2025), strategic distribution in Spain, enrollment of the U.S. pivotal trial, and subsequent commercial and regulatory updates including an approximate $400,000 order in Spain and Australia/New Zealand approvals announced July 1, 2025. Financing activity included at-the-market sales (~$5.5M in H1 2025) and a June 2025 underwritten offering (gross $4.51M, net proceeds $3.705M). Management states substantial doubt exists about the company’s ability to continue as a going concern and discloses Nasdaq non-compliance notices with deadlines to regain compliance.
Femasys Inc. announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to this Current Report; the text states the release is being furnished, not "filed," under the Exchange Act and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings. This 8-K text does not include financial figures or operating metrics; readers must consult Exhibit 99.1 for the detailed results and corporate update. The filing identifies the company as an emerging growth company and shows its Nasdaq ticker as FEMY.
Femasys Inc. (Nasdaq: FEMY) filed a Form 8-K to disclose a material event under Item 8.01 (Other Events).
- On July 1, 2025, the Company issued a press release (Exhibit 99.1) announcing that it has obtained regulatory approvals in Australia and New Zealand for two products:
- FemaSeed for first-line infertility treatment
- FemVue diagnostic system
- No financial results, transaction details, or forward-looking guidance were included in the filing.
- The disclosure is limited to the announcement; the full press release is incorporated by reference but not reproduced in the 8-K.
The Company indicates it remains an emerging growth company.
Femasys (NASDAQ: FEMY) held its Annual Meeting of Stockholders on June 25, 2025, with 59.41% of eligible shares represented. Three key proposals were voted on:
- Director Elections: Two Class I directors were elected for three-year terms through 2028: - Alistair Milnes (4.88M votes for, 941K against) - Edward Uzialko (4.95M votes for, 876K against)
- Equity Incentive Plan Amendment: Stockholders approved increasing authorized shares under the 2021 Plan by 3 million shares (4.26M votes for, 1.58M against)
- Auditor Appointment: KPMG LLP was ratified as independent auditor for FY2025 with overwhelming support (16.10M votes for, 80K against)
The company, listed as an emerging growth company, has elected not to use extended transition periods for new accounting standards compliance.